Transcranial magnetic stimulation for obsessive-compulsive disorder and post-traumatic stress disorder

• Verfasst von: Vicheva, Petya [VerfasserIn]
• Verfasst von: Osborne, Curtis [VerfasserIn]
• Verfasst von: Krieg, Sandro [VerfasserIn]
• Verfasst von: Ahmadi, Rezvan [VerfasserIn]
• Verfasst von: Shotbolt, Paul [VerfasserIn]
• Titel: Transcranial magnetic stimulation for obsessive-compulsive disorder and post-traumatic stress disorder
• Titelzusatz: A comprehensive systematic review and analysis of therapeutic benefits, cortical targets, and psychopathophysiological mechanisms
• Verf.angabe: Petya Vicheva, Curtis Osborne, Sandro M. Krieg, Rezvan Ahmadi, Paul Shotbolt
• E-Jahr: 2025
• Jahr: 10 January 2025
• Umfang: 25 S.
• Fussnoten: Gesehen am 26.02.2025
• Titel Quelle: Enthalten in: Progress in neuro-psychopharmacology & biological psychiatry
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1982
• Jahr Quelle: 2025
• Band/Heft Quelle: Volume 136 (10 January 2025), 111147, Seite [1]-25
• ISSN Quelle: 1878-4216
• DOI: doi:10.1016/j.pnpbp.2024.111147
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cortical target selection
• Sach-SW: Neuromodulation
• Sach-SW: Obsessive-compulsive disorder
• Sach-SW: Post-traumatic stress disorder
• Sach-SW: Systematic review
• Sach-SW: Transcranial magnetic stimulation
• K10plus-PPN: 191861296X

Abstract

Transcranial magnetic stimulation (TMS) is a safe non-invasive treatment technique. We systematically reviewed randomised controlled trials (RCTs) applying TMS in obsessive compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) to analyse its therapeutic benefits and explore the relationship between cortical target and psychopathophysiology. We included 47 randomised controlled trials (35 for OCD) and found a 22.7 % symptom improvement for OCD and 29.4 % for PTSD. Eight cortical targets were investigated for OCD and four for PTSD, yielding similar results. Bilateral dlPFC-TMS exhibited the greatest symptom change (32.3 % for OCD, N = 4 studies; 35.7 % for PTSD, N = 1 studies), followed by right dlPFC-TMS (24.4 % for OCD, N = 8; 26.7 % for PTSD, N = 10), and left dlPFC-TMS (22.9 % for OCD, N = 6; 23.1 % for PTSD, N = 1). mPFC-TMS showed promising results, although evidence is limited (N = 2 studies each for OCD and PTSD) and findings for PTSD were conflicting. Despite clinical improvement, reviewed reports lacked a consistent and solid rationale for cortical target selection, revealing a gap in TMS research that complicates the interpretation of findings and hinders TMS development and optimisation. Future research should adopt a hypothesis-driven approach rather than relying solely on correlations from imaging studies, integrating neurobiological processes with affective, behavioural, and cognitive states, thereby doing justice to the complexity of human experience and mental illness.